After conducting a clinical trial study at Boston Children’s Hospital, scientists from Brown University recommended that a lonafarnib therapy could increase the survival rate of progeria patients. But the mode of action of lonafarnib is still uncertain.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.